01—Abstract
Summary
Summary of the 10-K filed November 26, 2024. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) reported a strong fiscal year 2024, with revenue increasing by 12.1% to $293.96 billiona, driven primarily by growth in its U.S. Healthcare Solutions segment.
This growth was fueled by increased unit volumes, notably in GLP-1 class drugs for diabetes and weight loss, specialty products, and COVID-19 therapies and vaccines. The company also experienced robust gross profit growth of 10.6%, benefiting from increased sales and a favorable shift from LIFO expense to a LIFO credit. However, operating expenses saw a significant increase of 16.9%, largely due to a $418 millionb goodwill impairment related to PharmaLex and increased litigation and opioid-related expenses.
Despite these headwinds, total segment operating income grew by 10.9%, showcasing the underlying strength of its core businesses. A major development during the year was the agreement to acquire Retina Consultants of America (RCA) for approximately $4.6 billionc, signaling a strategic move into new growth areas, funded by a combination of cash and debt.
Cencora continues to prioritize shareholder returns, with a consistent increase in quarterly dividends and ongoing share repurchase programs. The company's financial health remains solid, supported by strong operating cash flows and access to credit facilities, although it faces ongoing industry challenges such as pricing pressures and regulatory complexities.
02—Key points
Key Highlights
- Revenue increased by 12.1% to $293.96 billion in fiscal 2024, driven by strong performance in the U.S. Healthcare Solutions segment, particularly in GLP-1 drugs and specialty products.
- Gross profit grew by 10.6% to $9.91 billion, reflecting higher sales and a favorable LIFO credit.
- Operating expenses increased by 16.9% due to a $418 million goodwill impairment for PharmaLex and higher litigation/opioid expenses.
- Total segment operating income increased by 10.9% to $3.65 billion, indicating healthy core business performance.
- Cencora announced a significant acquisition of Retina Consultants of America (RCA) for approximately $4.6 billion, aiming to expand its strategic offerings.
- The company demonstrated commitment to shareholders with an 8% increase in its quarterly dividend to $0.55 per share and continued share repurchases.
- Operating cash flow remained strong at $3.5 billion, supporting ongoing operations and strategic investments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Cencora, Inc. kept $0.01.
- Revenue$293.96B100.0%
- Cost of revenue−$284.05B96.6%
- Gross profit$9.91B3.4%
- Operating costs−$7.73B2.6%
- Operating income$2.18B0.7%
- Interest, other & tax−$666.1M0.2%
- Net income$1.51B0.5%
Where FY2024 revenue went
$293.96B- Cost of revenue: $284.05B, 97% of revenue
- Net income: $1.51B, 0.5% of revenue
- SG&A: $5.66B, 1.9% of revenue
- Other operating costs: $2.07B, 0.7% of revenue
Kept 0.5% as net incomeNet income $1.51B · 0.5%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed November 26, 2024Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $293.96B$262.17B | +12.1% |
| Cost of Revenue | $284.05B$253.21B | +12.2% |
| Gross Profit | $9.91B$8.96B | +10.6% |
| SG&A Expenses | $5.66B$5.31B | +6.6% |
| Operating Expenses | $6.09B$5.72B | +6.5% |
| Operating Income | $2.18B$2.34B | −7.1% |
| Net Income | $1.51B$1.75B | −13.5% |
| EPS (Basic) | $7.60$8.62 | −11.8% |
| EPS (Diluted) | $7.53$8.53 | −11.7% |
| Shares Outstanding (Basic) | 198.50M202.51M | −2.0% |
| Shares Outstanding (Diluted) | 200.28M204.59M | −2.1% |
05—Questions
Frequently Asked Questions
What were the primary drivers of Cencora's revenue growth in fiscal year 2024?
Cencora's revenue growth of 12.1% in fiscal year 2024 was primarily driven by an increase in unit volume within its U.S. Healthcare Solutions segment. Key contributors included higher sales of GLP-1 class drugs for diabetes and weight loss, increased sales of specialty products to physician practices and health systems, and growth in sales of COVID-19 therapies and vaccines.
What is the significance of the goodwill impairment charge recognized in fiscal year 2024?
Cencora recognized a $418 million goodwill impairment charge in fiscal year 2024 related to its PharmaLex reporting unit. This impairment reflects a weakening demand for specialized services in the life sciences industry and a revision of PharmaLex's long-range forecast, impacting the carrying value of goodwill.
What are the implications of the announced acquisition of Retina Consultants of America (RCA)?
The announced acquisition of Retina Consultants of America (RCA) for approximately $4.6 billion signifies a strategic expansion for Cencora into new growth areas. This move is expected to enhance its service offerings and market position, although it will be financed through a combination of cash and new debt, increasing leverage.
How is Cencora managing its opioid litigation liabilities?
Cencora has accrued a litigation liability of $4.9 billion as of September 30, 2024, related to the Distributor Settlement Agreement and other opioid-related litigation, which is expected to be paid over 14 years. The company continues to litigate and defend itself in these matters, noting that the ultimate outcome and amount of loss may differ from the current accrual.
06—Continue